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Introduction
Cumulative measures of exposure are widely used in different areas of epidemiologic research in the estimation of the effects associated with exposures over time [1] . In infectious diseases epidemiology, cumulative viral load (cVL), or viremia copy-years, has been proposed as an estimate of the cumulative exposure to raised HIV-RNA viral load (VL) in individuals infected with human immunodeficiency virus (HIV). This cumulative exposure measure has high biological plausibility: raised VL is the primary marker of both disease control and infection transmission risk [2] . In individuals receiving antiretroviral therapy (ART), raised VL is associated with treatment failure and poor long-term treatment outcomes [3] . Cumulative exposure to raised VL has been hypothesised as a potential risk factor, or predictor of poor outcomes [4] [5] [6] . cVL appears to have been introduced independently by Zoufaly et al. [7] and Cole et al. [8] in association with outcomes related to the development of acquired immune deficiency syndrome (AIDS). Subsequently, variants of cVL appeared in use across a variety of studies, where the measure was often intended as a potential risk factor to predict outcomes such as all-cause mortality [4] [5] [6] 9, 10] . The empirical evidence for cVL as a useful prognostic factor for long term outcomes is mixed. While there is a biological argument to be made that the cumulative exposure to raised VL [11, 12] could be predictive of health outcomes, the empirical measurement of cumulative exposure by cVL has failed to demonstrate consistent associations.
For example, Cates et al [13] conclude that cVL burden prior to pregnancy is not informative in a study of risk of pregnancy loss among HIV infected women, but current VL appears highly predictive. In a follow up efficacy study comparing the antiretroviral drugs efavirenz and boosted lopinavir, cautious optimism was expressed towards the use of cVL as a prognostic factor [14] . Kukoyi et al [15] found that a log10 copies/mL/year measure to evaluate morbidity outcomes in a paediatric cohort was predictive, but the VL measure is included in analyses as a discrete variable, with just three levels. Kowalkowski et al [16] also found associations in subanalyses between a measure of cVL and non-AIDS defining malignancies, utilising a complex series of data imputation on 7-day follow up windows. Taken together, it remains unclear if cVL has greater utility then current or most recent VL.
Common concerns related to cumulative measures of exposure in epidemiology include timebased dependence of exposure and the method of measurement (direct or indirect) [7] . cVL may be defined as the area under the plasma VL curve and has been calculated using copies/mL or log10 copies/mL. However, the phrase "under the curve" is not precise, as VL is not continuously measured over time, but sampled at discrete time points, and therefore the true individual trajectory is unknown and the area must be approximated using integral approximation methods. Some of the mixed empirical results in estimating the association of cVL to health outcomes may be due to the inconsistencies in estimation. The majority of analyses estimate cumulative viremia or viral copy-years using the trapezoidal rule, which sums the areas between two successive points joined by linear interpolation [17] . While it has been established that this method is scale dependent [18] , no research has examined the impact of sampling frequency bias. Here we estimate the bias due to changes in sampling frequency when estimating cVL by the trapezoidal rule. We utilise two empirical and one simulated data set, each with repeated VL measures, to estimate the magnitude and direction of the bias in the estimation of cVL and make recommendations for improved usage.
Methods

Data sources
We used three different data sources to examine how sampling time points effect cVL estimation: an intensively monitored cohort of women initiating ART [11] , a simulated data set of longitudinal HIV VL trajectories developed for a monitoring study [19] , and a random sample of routine VL data collected by the South African National Health Laboratory Services (NHLS) [20] . The two empirical datasets were selected to reflect different types of data collection, either under intensive health research and follow-up or under routine care and with different expected longitudinal VL trajectories drawing from different populations. The inclusion of simulated data provides an opportunity to evaluate estimation of cVL at different sampling frequencies against a known 'truth'.
The cohort study has VL measures of 518 women initiating ART during pregnancy and followed up to approximately 18 months postpartum. This is a frequently measured cohort with a median of 7 VL measures during the follow up, which is much more frequent than most routine clinical settings. The routine monitoring sample includes n = 29,519 individuals, who were not virally suppressed for the entire duration of follow-up and had a minimum of 5 VL measures from the NHLS data set. The sample is extracted from routine laboratory data comprised of individuals in ART programmes in the Western Cape, South Africa. This routinely collected monitoring data has either 6 or 12 months between VL measures, on average, following South African treatment guidelines [21] . The simulated dataset is contributed from a model of longitudinal VL trajectories for 80 weeks on a weekly time step [20] . The data is simulated to mimic trajectories and conditions of patients initiating ART during and contains a simulated sample of 10,000 individuals.
This study is an analysis of secondary data which was originally collected by studies carried out 
Estimation of cVL
Log10 VL measures are used throughout in the calculation of cVL. cVL is calculated for each time series using the trapezoidal rule which uses a linear approximation between successive points (Equation 1 and Figure 1 ). VL measures below 50 copies per mL are set to zero to avoid an increase in cVL while below the limit of detection. In addition to estimating cVL over the given time frame (between first and last VL observations, regardless of total duration of observation)
we calculate a standardised cVL that adjusts for individual follow-up time (Equation 2). Median (interquartile) range of the individual estimates of cVL are reported.
Subsampling
We calculate cVL based on subsets of the available data and compare these estimates to the cVLREF, which uses every data point in the full time series. We use two different subsampling strategies: a) random subsample to a set number of VL measures (n=2 -5), ensuring that the first and last VL measure per individual are always retained to ensure consistency with total follow up time and b) sampling based on average interval between VL measures, retaining the first and last VL measure per individual. Median and interquartile ranges for estimated cVL are provided, as well as the percent change compared to cVLREF. This estimate reflects both the viremia and duration of follow up of individuals in the respective data sets. A follow-up standardised measure is also calculated and reported in order to reduce the dependence on the individual's total duration of follow-up. This measure is analogous to the viral copy-year. The cVLFU is calculated using all available VL measures, and then individually standardised for total follow-up time. Cohort viral load trajectories were visualised using generalised additive model smoothing with a natural b-spline. 
Results
Characteristics of the three data sets can be found in Table 1 The cVLREF is calculated using all available VL measures in each data set and represents the most accurate possible measure of cVL ( Table 2 ). The median cVL measure is 0.49 log10 copies/mL years (IQR: 0.20-0.97 log10 copies/mL years) using the cohort data, 7.39 log10 copies/mL years (IQR: 4.55-11.41 log10 copies/mL years) in the routine monitoring laboratory data, and 2.08 log10 copies/mL years (IQR: 1.84-2.72 log10 copies/mL years) in the simulated data. The median standardised cVL measure in the cohort is 0.50 log10 copies/mL year (IQR: 0.23-1.34 log10 copies/mL year), in the routine laboratory data 2.10 log10 copies/mL year (IQR: 1.29-3.12 log10 copies/mL year), and in the simulated data 2.09 log10 copies/mL year (IQR: 1.57-2.24 log10 copies/mL year). Meaningfully large differences in estimated cVL are found between cVLREF compared to random subsamples with reduced numbers of observations (Table 2 ). There is a significant and meaningful bias towards overestimation, ranging from +50% to +344% change compared to cVL reference in the cohort, and a +16% to +44% change from reference in the simulated data, both of which reflect short duration (<2 years) follow-up. The routine monitoring data demonstrates a different pattern of bias of small but consistent overestimation of between +3% to +4% from reference cVL. This consistency is partially reflective of the high proportion (39%) of observations that are <50 copies/mL and the overestimation increases when the proportion of VL measures <50 copies/mL decreases. Use of the follow-up standardised reference measure reduces the extent of the bias in the cohort and simulation data, where it ranges from +18% to +301% (cohort) and +5% to +27% (simulation). In the routine laboratory data the change from reference remained consistently positive and ranged from +2% to +5%. In general, the different subsamples give estimates further away from the reference measure as the number of subsamples decreases (Table 2 ). When evaluating the subsamples where sampling was based on increasing the mean duration between VL measures, there was an increasing positive bias in the estimation of cVL, from +7%
to +20% as the duration between samples increases from 4 weeks to 24 weeks. The empirical cohort data demonstrates the same trend, but with much larger bias, ranging from +36% at 4
weeks minimum duration to +335% at 24 weeks minimum duration between samples. It is important to note that the sample size reduces as the duration between samples increases in the cohort data. Estimation of the follow-up time standardised version of cVL for the same subsets indicates a similar tendency, but with a slightly smaller magnitude of bias compared to the nonstandardised estimates, ranging to only +9% in the simulated data to +299% in the cohort data (Table 3) . 
Discussion
Estimating the true cumulative exposure by approximating the area under a curve using repeat measures of a biomarker such as VL on time scales that are routine in clinical care (weeks to months) is subject to a number of sources of bias. As the "true" shape of the trajectory between measurements is unknown, approximation of cVL has typically been by a crude method of geometric approximation known as the trapezoidal rule. In most empirical work with repeated measures of VL, the sparsity of VL measures over time ensures that accurate approximation of the true trajectory is unlikely. Even within a single study, unless VL measures occur with the same timing and frequency for every individual, the measure of cVL may be more reflective of sampling frequency bias than any underlying biological mechanism: cVL for individuals with fewer, or more widely spaced measures will be inaccurate and biased upwards compared to individuals with more, or more frequent, VL measures. example, pack-years in smoking exposure, are routinely compared across studies, it is necessary to do so with an assumption that the underlying exposure is not changing substantially over time, though this is rarely stated.
Some approaches to reducing the impact of sampling bias have been applied. Mugavero et al. [4] use inverse weights to adjust for sampling frequency, resulting in a positive association between cVL and mortality outcomes. However, this approach is only applicable in the case where a reasonable approach to estimation of the inverse weights is possible. Other integral estimation methods are available, for example, composite Simpson's rule [17] which uses a third order polynomial to interpolate between successive points, and is know to be more accurate than trapezoidal estimation [17] , but requires evenly spaced time points which are uncommon in most cohort studies. Another approach may be to avoid attempts at cumulative viraemia exposures altogether in favour of simpler measures which may be more directly interpretable [22] . Finally, we note that the use of the term cumulative viremia or viral-copy-years is non-precise, as different researchers have utilised slightly different definitions, both in terms of using copies/mL vs log10 copies/mL, different handling of VL measures below the limit of detection and different methods of follow-up duration standardisation. The key point here is that without standardisation of the estimate, and without an explicit process for managing sampling frequency and other sources of obvious bias, the measures of cumulative exposure to raised HIV viral load cannot be presumed consistent and are unlikely to be comparable across studies.
In summary, cVL exposure estimates should be used with caution as they will tend to overestimate the true exposure to raised viremia, and should not be used as an absolute measure of comparison between studies or cohorts with different frequencies of VL monitoring.
Utilisation of cVL as a relative measure within a well characterised and consistently observed cohort may provide useful relative estimates of differential exposure to raised viral load over time.
